Search results
Results from the WOW.Com Content Network
The treatment saved my life but also pushed me into medically-induced menopause at the age of just 37. By this visit, my cancer was thankfully in remission and I was going to live to see my two ...
There is a non-statistically significant increased rate of breast cancer for hormone replacement therapy with synthetic progestogens. [6] The risk may be reduced with bioidentical progesterone, [69] though the only prospective study that suggested this was underpowered due to the rarity of breast cancer in the control population.
Average number of moderate-to-severe hot flashes per week with placebo and different doses of oral estradiol in menopausal women [40] [41]. Estradiol is used in menopausal hormone therapy to prevent and treat moderate to severe menopausal symptoms such as hot flashes, vaginal dryness and atrophy, and osteoporosis (bone loss). [11]
Currently there is a large study sponsored by the National Cancer Institute that is ongoing, but not accepting any new participants. [37] The rationale for the study is that estrogen can relieve the symptoms of menopause, but can also cause the growth of breast cancer cells.
Cessation of menses as a result of removal of the ovaries is called "surgical menopause". Surgical treatments, such as the removal of ovaries, might cause periods to stop altogether. [55] The sudden and complete drop in hormone levels may produce extreme withdrawal symptoms such as hot flashes, etc. The symptoms of early menopause may be more ...
Treatment of postmenopausal women with 2.5 or 5 mg/day MPA in combination with estradiol valerate for two weeks has been found to rapidly increase circulating MPA levels, with steady-state concentrations achieved after three days and peak concentrations occurring 1.5 to 2 hours after ingestion.
Breast atrophy is the normal or spontaneous atrophy or shrinkage of the breasts. [1]Breast atrophy commonly occurs in women during menopause when estrogen levels decrease. [2] [3] [4] It can also be caused by hypoestrogenism and/or hyperandrogenism in women in general, [1] such as in antiestrogen treatment for breast cancer, in polycystic ovary syndrome (PCOS), [5] [6] and in malnutrition such ...
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.